Neutrolis

L302 Clin0 neuroendocrine tumors; L303 Clin0 neuroendocrine tumors; L304 Clin0 ocular inflammation; L305 thrombo-inflammation; L200 RD respiratory inflammation

Neutrolis is a clinical-stage company focused on developing innovative therapies that target neutrophils, the most abundant immune cells in the body. Their research centers around neutrophil extracellular traps (NETs), which are harmful structures released by neutrophils that can contribute to various diseases. Neutrolis is focused on developing therapies for autoimmune and inflammatory conditions such as lupus, rheumatoid arthritis, and systemic sclerosis, where NETs play a significant role. Their proprietary exDNAase™ platform analyzes naturally occurring DNAase enzymes and then designs the prototype of engineered DNAses that can then disassemble NETs. They are exploring the potential of their therapies for treating severe infections, including COVID-19. Neutrolis’s lead product, L301, is a first-in-class DNASE1L3 enzyme analog designed to break down NETs and reduce inflammation. It is currently being developed for the treatment of severe COVID-19 and other NET-mediated diseases. There are a number of products in Neutrolis’s pipeline.

Jobs: